Panel Discussion: Target-Focused vs High-Throughput Approaches for Discovering Therapeutically Effective RNA-Targeting Small Molecules

• What are the advantages and challenges associated with target-focused approaches?
• What are the advantages and challenges associated with high-throughput phenotypic or cell-based functional screening approaches?
• How is phenotypic RNA modulation connected back to a specific RNA target, binding site, or mechanism of action?
• How does each approach manage generating actionable SAR and program attrition?

Speakers:

Matt Smola

Associate Director - RNA Biology

Ribometrix

Jennifer Petter

Founder & Former Chief Scientific Officer

Arrakis Therapeutics Inc.

David Weitz

Chief Executive Officer & Founder

Syrna Therapeutics Inc

Domi Stickens

Chief Scientific Officer

Arrakis Therapeutics Inc.